A person enrolled in a clinical trial receives the COVID vaccine. Employers' vaccine mandates came under scrutiny during the ...

ALK will also pay up to $320m in milestone payments to ARS in the deal, which sees the latter keep rights in the US, ...

Revenue growth is due to growth in Teva's US generics business, the company's main market, among other things due to sales of ...

I have long held the belief that digital therapeutics will be prescribed alongside drugs to improve patient outcomes, leading ...

In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a price target of $25.00. The company’s shares closed last Friday ...

The company’s shares closed last Friday at $8.73. Prasad covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical, Elanco Animal Health, and Jazz Pharmaceuticals. According to ...